Neuroimmunology Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 37.80 Bn

Forecast Year, 2035

USD 91.88 Bn

CAGR, 2026 - 2035

8.90%

Report Coverage

Global

Neuroimmunology Market Size and Forecast: 2025 to 2035

The global neuroimmunology market size accounted for USD 37.80 billion in 2025 and is predicted to increase from USD 41.15 billion in 2026 to approximately USD 91.88 billion by 2035, expanding at a CAGR of 8.90% from 2026 to 2035. The market is driven by the surging global incidence of neurological and autoimmune disorders, such as multiple sclerosis, Alzheimer's, and Parkinson's, combined with breakthroughs in targeted drug discovery and advanced diagnostic imaging.

Key Takeaways

• North America dominated the global neuroimmunology market with a share of 39% in 2025.
• Asia-Pacific is expected to grow at the fastest CAGR of 13.5% during the forecast period.
• By disease type, the multiple sclerosis segment led the global market with a share of 36% in 2025.
• By disease type, the neuroinflammatory disorders segment held 9% of the market share in 2025 and is expected to grow at the fastest CAGR of 12.5% between 2026 and 2035.
• By treatment type, the monoclonal antibodies segment accounted for a revenue share of 30% in the market in 2025.
• By treatment type, the cell-based therapies segment is expected to grow at the highest CAGR of 18.5% between 2026 and 2035.
• By mechanism of action, the B-cell targeting therapies segment accounted for the highest revenue share of 28% in the market in 2025.
• By mechanism of action, the complement inhibition segment is expected to grow at the fastest CAGR of 14.5% between 2026 and 2035.

Global Market Overview and Key Metrics

The neuroimmunology industry refers to the global pharmaceutical, biotechnology, and diagnostic sectors aimed at treating conditions that arise from complex interactions between the nervous system and the immune system. It mainly covers drugs and medical tests for neuroinflammatory and autoimmune disorders. The primary driving factor for the market is the rapidly growing global incidence of neurological and autoimmune disorders, like multiple sclerosis (MS), Alzheimer's, and autoimmune encephalitis.

How is AI Influencing the Neuroimmunology Market?

Artificial intelligence (AI) is profoundly changing the neuroimmunology industry by accelerating drug discovery, enabling highly accurate differential diagnostics, and paving the way for personalized therapeutic strategies. By decoding complex neuroimmune interactions, AI is assisting researchers and clinicians in tackling previously intractable brain diseases. AI systems and predictive models harmonize large-scale longitudinal datasets, electronic health records (EHR), and multi-omics information. This enables healthcare providers to simulate diverse treatment scenarios and forecast the exact course of an individual's disease.

Key Neuroimmunology Market Trends 2026: Biologics, AI Drug Discovery & Precision Medicine

• The market is rapidly moving toward targeted biologic therapies, like monoclonal antibodies, which provide more precise immune modulation for complex neuro-autoimmune conditions.
• Pharmaceutical firms are leveraging AI to screen compounds, repurpose existing drugs, and forecast drug-target interactions, which accelerates the discovery of new disease-modifying treatments.
• Advancements in pharmacogenomics, next-generation sequencing, and biomarker integration are allowing customized treatment plans, minimizing adverse side effects, and thus reducing trial-and-error prescribing.

Market Report Coverage and Key Metrics

Market Dynamics and Growth Drivers

Drivers

Increased Awareness of Neuroimmunological Disorders

Increased awareness of neuroimmunological disorders is the essential driver of the neuroimmunology market. It expands the actionable patient pool, drives early and accurate diagnoses using advanced biomarkers, and even accelerates R&D investments into targeted biologic and monoclonal antibody therapies. Patient and physician advocacy has accelerated funding into targeted immunotherapies, specifically monoclonal antibodies, programmed to modify disease progression rather than just manage symptoms.

Restraint

High Cost of Therapies and Testing

The high cost of therapies and testing is a primary restraint in the market because it drives severe financial toxicity and even creates access barriers for patients. These expenses restrict widespread adoption, limit availability in developing regions, and lead to prescription abandonment or delayed diagnoses. In developing and low-to-middle-income countries, the shortage of robust universal healthcare coverage and low patient affordability severely curtail market penetration.

Opportunity

Emergence of CAR T-Cell & Targeted Biologic Therapies

The emergence of CAR T-cell and targeted biologic therapies is the primary growth engine for the market. These breakthroughs enable deep immune reprogramming and targeted destruction of autoreactive cells, changing treatment paradigms from lifelong, broad immunosuppression to highly precise, thus curative interventions for severe, treatment-refractory neurological diseases.

Market Segmentation Analysis

Disease Type Insights

The Multiple Sclerosis Segment Held the Largest Market Share of 36% in 2025

The multiple sclerosis segment generated approximately USD 13.61 billion in 2025 and is projected to reach nearly USD 30.32 billion by 2035, growing at a CAGR of 7.5% during the forecast period. The multiple sclerosis segment dominated the neuroimmunology market with a share of 36% in 2025, owing to the high global prevalence, strong therapeutic pipeline, and increasing acceptance of disease-modifying biologics. Pharmaceutical firms and academic institutions are investing heavily in a pipeline of next-generation therapies, which includes trials for myelin repair and even progressive forms of multiple sclerosis.

Neuroimmunology Market Share, By Disease Type, 2025-2035 (%)

The neuromyelitis optica spectrum disorder (NMOSD) segment accounted for approximately USD 5.29 billion in 2025 and is projected to reach nearly USD 14.70 billion by 2035, growing at a CAGR of 11.2% during the forecast period The neuromyelitis optica spectrum disorder (NMOSD) segment held the second-largest market share of 14% in 2025, driven by the rising awareness, early diagnosis of NMOSD, and increasing adoption of monoclonal antibody therapies. Epidemiological data and broader screening have uncovered previously underreported NMOSD cases, creating a larger addressable patient population.

The neuroinflammatory disorders segment generated approximately USD 3.40 billion in 2025 and is projected to reach nearly USD 10.11 billion by 2035, growing at the fastest CAGR of 12.5% during the forecast period. The neuroinflammatory disorders segment held a 9% share of the market in 2025. This is mainly due to the growing research on neuroinflammation pathways and the increasing adoption of anti-inflammatory biologics. Advanced imaging, like high-resolution MRI and PET scans, and high-throughput biomarker assays, such as cerebrospinal fluid, now enables earlier and highly specific disease subtyping.

Treatment Type Insights

The Monoclonal Antibodies Segment Held the Largest Market Share of 30% in 2025

The monoclonal antibodies segment generated approximately USD 11.34 billion in 2025 and is projected to reach nearly USD 33.08 billion by 2035, growing at a CAGR of 12.8% during the forecast period. The segment dominated the neuroimmunology market with a share of 30% in 2025, owing to the rapid adoption of targeted biologic therapies and increasing approvals for neuroimmune disorders. Landmark regulatory approvals for transformative treatments such as Ocrevus (ocrelizumab) for multiple sclerosis have proven the clinical and commercial viability of neuroimmunological mAbs.

Neuroimmunology Market Share, By Treatment Type, 2025-2035 (%)

The immunomodulators segment accounted for approximately USD 9.07 billion in 2025 and is projected to reach nearly USD 18.38 billion by 2035, growing at a CAGR of 6.5% during the forecast period. The cell-based therapies segment held 4% of the market share in 2025. This is mainly due to the increasing research in stem cells and regenerative neurology and the rising focus on immune system reprogramming. The unprecedented efficacy of chimeric antigen receptor (CAR-T) T-cell therapies in hematologic malignancies has paved the way for treating refractory autoimmune conditions, which impact the central and peripheral nervous systems.

The cell-based therapies segment generated approximately USD 1.51 billion in 2025 and is projected to reach nearly USD 6.43 billion by 2035, growing at the fastest CAGR of 18.5% during the forecast period. The immunomodulators segment held a 24% share of the market in 2025, driven by the strong usage in multiple sclerosis and autoimmune neurological disorders, and the growing availability of oral disease-modifying therapies. The growing introduction of biosimilars and follow-on biologics is lowering the historically high costs linked with biological therapies, thereby enhancing patient access and affordability in emerging economies.

Mechanism of Action Insights

Neuroimmunology Market Share, By Mechanism of Action, 2025-2035 (%)

Why Did the B-cell Targeting Therapies Segment Lead the Neuroimmunology Market?

The B-cell targeting therapies segment generated approximately USD 10.58 billion in 2025 and is projected to reach nearly USD 29.40 billion by 2035, growing at a CAGR of 13.0% during the forecast period. The segment held the largest share of 28% in 2025, driven by the rising acceptance of rituximab and anti-CD20 therapies and the rising success in autoimmune neurological diseases. Drugs targeting specific B-cell markers, such as CD20, deplete immature and mature B-cells while sparing early precursor cells and even long-lived plasma cells. This enables the patient to retain a large portion of their long-term humoral immune memory, offering a robust treatment that still preserves natural defense mechanisms.

The complement inhibition segment accounted for approximately USD 3.78 billion in 2025 and is projected to reach nearly USD 11.03 billion by 2035, growing at the fastest CAGR of 14.5% during the forecast period. The complement inhibition segment held a 10% share of the market in 2025. This is mainly because of the rising acceptance of complement inhibitors in NMOSD and myasthenia gravis, and rising approvals of targeted complement therapies. Regulatory bodies such as the U.S. FDA and EMA have consistently granted Orphan Drug designations along with accelerated approval pathways, bringing clinical-stage neuroimmunology drugs into the market much faster.

The T-cell modulation segment generated approximately USD 6.80 billion in 2025 and is projected to reach nearly USD 14.70 billion by 2035, growing at a CAGR of 7.2% during the forecast period. The T-cell modulation segment held a 18% share of the market in 2025, driven by the continued use in multiple sclerosis therapies and increasing immunology research in T-cell pathways. Groundbreaking research into how T-cells are regulated has driven massive R&D investments. The discovery of peripheral immune tolerance and how Tregs act as a defense against autoimmune diseases has transformed drug pipelines.

Market Regional Analysis: North America, Europe, Asia-Pacific

North America Neuroimmunology Market Size and Growth 2026 to 2035

The North America neuroimmunology market size was exhibited at USD 14.74 billion in 2025 and is projected to be worth around USD 30.00 billion by 2035, growing at a CAGR of 7.80% from 2026 to 2035.

Which Factors Supported North America's Dominance in the Neuroimmunology Market?

North America dominated the market with a major share of 39% in 2025. This dominance is supported by the high prevalence of neuroimmune and autoimmune neurological disorders and the strong acceptance of biologics and monoclonal antibody therapies. Innovations in biomarker detection, the integration of AI-enabled neuroimaging, and next-generation sequencing enable earlier and more accurate diagnoses.

U.S. Neuroimmunology Market Size and Growth 2026 to 2035

The U.S. neuroimmunology market size was evaluated at USD 11.58 billion in 2025 and is projected to reach around USD 27.79 billion by 2035, growing at a CAGR of 7.85% from 2026 to 2035.

U.S. Market Analysis

The U.S. market is driven by the increasing prevalence of autoimmune neurological disorders, increased R&D investments, and regulatory approvals for targeted therapies, for instance, monoclonal antibodies and biologics. Favorable government initiatives, strong healthcare reimbursement frameworks, and continuous clinical trials sponsored by major biopharma firms ensure a robust drug pipeline.

How is Europe Growing in the Neuroimmunology Market?

Europe held the second-largest market share of 30% in 2025 and is expected to grow at a notable CAGR of 7.5% during the projection period, driven primarily by strong public healthcare systems supporting neuroimmune treatments and increasing focus on precision neurology and biologics. Progress in biologicals and small-molecule drug discovery, coupled with the expanded usage of biologics and targeted therapies, has revolutionized patient care pathways.

UK Market Analysis

The UK market is mainly driven by an aging population, the rising prevalence of autoimmune and neurological conditions, and heavy investments in neurological drug and biomarker research. A robust healthcare infrastructure and strategic government backing have further accelerated expansion in this specialized medical sector.

Will Asia-Pacific Grow in the Neuroimmunology Market?

Asia-Pacific held a 22% share of the market in 2025 and is expected to grow at the fastest CAGR of 13.5% during the projection period, driven by the rapidly expanding healthcare infrastructure in China and India, increasing awareness, and diagnosis of neuroimmune disorders. Increased patient knowledge regarding neurological health and the push for early disease detection have directly led to higher diagnostic testing rates along with clinical trial activities across the region.

China Market Analysis

China's market is mainly driven by supportive government reforms for innovative drugs, enhanced early diagnostic capabilities, and greater inclusion of rare, autoimmune conditions, like multiple sclerosis, in national medical reimbursement lists. Massive increases in venture capital and even domestic research have led to breakthroughs in biological and small-molecule drug discoveries. Moreover, next-generation sequencing and genomic studies are driving personalized medicine, enabling therapies to target specific gene mutations linked with complex neurological conditions.

What Drives the Neuroimmunology Market in Latin America?

Latin America held a 6% share of the market in 2025 and is expected to grow at a CAGR of 6.5% in the upcoming period. This is mainly due to the rising prevalence of neurological and autoimmune disorders such as multiple sclerosis, myocarditis, and encephalitis, along with improving disease awareness among healthcare professionals. Strengthening diagnostic capabilities, expanding healthcare infrastructure, and increasing access to advanced immunotherapies and neurology treatments are further supporting regional growth.

Brazil Market Trends

Brazil is emerging as a major contributor to the Latin American neuroimmunology market due to its large patient base and rapidly expanding healthcare system. The country is witnessing growth in specialized neurology and immunology centers, supported by rising expertise in autoimmune neurological diseases and broader access to advanced treatments. In addition, public health initiatives and increasing investment in biologic therapies are accelerating the adoption of modern neuroimmunology care.

How is the Opportunistic Rise of the Middle East & Africa in the Neuroimmunology Market?

The Middle East & Africa held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 8.2% in the upcoming years, driven by the increasing incidence of autoimmune and neurological disorders, improvements in healthcare infrastructure, and rising investments in advanced diagnostic and treatment solutions. Expansion of neurology departments, greater availability of biomarker testing and MRI diagnostics, and increasing awareness of conditions such as multiple sclerosis are further contributing to market development.

Saudi Arabia Market Trends

Saudi Arabia is witnessing strong growth due to rising neurological disease prevalence and ongoing healthcare modernization initiatives. The country is investing in advanced diagnostic technologies, specialized neurology hospitals, and immunology research centers to strengthen disease detection and treatment capabilities. Furthermore, increasing adoption of biologic drugs and targeted immunomodulatory therapies within both public and private healthcare systems is supporting continued market expansion.

Market Competitive Landscape: Leading Companies and Strategies

The neuroimmunology market is highly competitive and innovation-driven, with leading pharmaceutical and biotechnology companies such as Sanofi, Roche, Novartis, Biogen, and Johnson & Johnson actively advancing research through collaborations, R&D investments, and development of next-generation biologics. These companies are focusing on innovative therapeutic modalities, particularly bispecific antibodies and advanced biologic platforms, to address complex autoimmune and inflammatory neurological conditions.

• For instance, Sanofi's collaboration with Earendil Labs ahead of JP Morgan 2026 reflects its strategic emphasis on developing bispecific antibodies for autoimmune and inflammatory diseases, highlighting the industry's shift toward highly targeted immunotherapies.

Technological innovation is reshaping competitive dynamics in the market, with artificial intelligence playing a key role in accelerating drug discovery, single-cell and gene profiling, next-generation biologics development, and precision medicine approaches. The increasing adoption of AI-driven platforms is improving disease understanding, enabling more personalized treatment strategies, and enhancing clinical outcomes in autoimmune neurological and central nervous system inflammatory disorders. As a result, companies that effectively integrate biologic innovation with AI-enabled research capabilities are expected to gain a significant competitive advantage in the evolving neuroimmunology landscape.

Neuroimmunology Market Leading Companies

• Biogen Inc
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Sanofi S.A.
• Bristol Myers Squibb
• Merck KGaA
• Alexion Pharmaceuticals
• AbbVie Inc.
• UCB Pharma
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• Johnson & Johnson

Recent Developments

• In February 2026, researchers from WashU Medicine and Weizmann Institute of Science engineered CAR-T cells to target amyloid beta plaques in the brain, offering a promising approach to treating the condition. The study showed positive results in mice, reducing harmful amyloid plaques and improving the overall brain tissue health. (Source: https://medicine.washu.edu/)
• In October 2025, Nilo Therapeutics announced the completion of its Series A funding round worth $101 million to support the establishment of Nilo's research labs in New York City, expand its interdisciplinary R&D team, and accelerate the development of its preclinical programs. (Source: https://pulse2.com)

Segments Covered in the Report

By Disease Type

• Multiple Sclerosis
• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Myasthenia Gravis
• Autoimmune Encephalitis
• Guillain-Barré Syndrome (GBS)
• Chronic Inflammatory Demyelinating Polyneuropathy
• Neuroinflammatory Disorders
• Other Neuroimmune Disorders

By Treatment Type

• Immunomodulators
• Immunosuppressants
• Monoclonal Antibodies
• Corticosteroids
• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange (PLEX)
• Cell-based Therapies
• Other Biologic Therapies

By Mechanism of Action

• B-cell Targeting Therapies
• T-cell Modulation
• Complement Inhibition
• Cytokine Inhibition
• Neuroprotection
• Anti-inflammatory Therapy

By Route of Administration

• Oral
• Injectable
• Intravenous (IV)
• Subcutaneous

By End-user

• Hospitals
• Specialty Neurology Clinics
• Research & Academic Institutes
• Homecare Settings
• Rehabilitation Centers

By Region

• North America
• Latin America
• Europe
• Asia-pacific
• Middle and East Africa